PhRMA, Others Look For Savings In Reduced Drug Interactions
Executive Summary
Reducing the instances of adverse events related to drug-drug interactions is among the options to reduce health care spending presented by both the Pharmaceutical Research and Manufacturers of America and the American Medical Association
You may also be interested in...
Policy Changes In Part D Could Improve Patients’ Rx Adherence, Professor Argues
Former MedPAC member Bruce Stuart offers policy recommendations that would make medication therapy management programs in the Medicare Part D more effective, with the goal of improving medication adherence.
Cost-Cutting Sequel Yields Little Surprise: PhRMA Supports Efficient Medication Use, More Drug Development, Expanded Access
Following up on their pledge to help reduce growing health costs, PhRMA, other health groups provide more specifics to President Obama.
Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine
As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.